EUROPEAN JOURNAL OF
PHARMACEUTICAL AND MEDICAL RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia ,

ISSN 2394-3211

Impact Factor: 6.222

ICV - 79.57

Abstract

FAVIPIRAVIR: A PRIMARY TREATMENT OF COVID-19

Shubham S. Shinde* and Rutuja S. Babar

ABSTRACT

Favipiravir generally comes under antiviral activity. Favipiravir shows pharmacokinetic and pharmacodynamic activity. The mechanism depends on RNA dependent. And it was effective against different viruses. Favipiravir is available in different combinations such as Hydro chloroquinoline, Oseltamivir, Theophylline, Raloxifene, Hydralazine, etc. The article grants a comparative duty of issued logical assessments either as separate drug or in combinations so that it is supportive for research professors worldwide. Favipiravir use in the treatment of not only COVID-19 but also in Nipah, Ebola, Influenza and other kinds of virus treatment also. The author here mentions drug interaction and dose level with also cover different parameters. Dose of favipiravir may cause a problem in uric acid. And also, wish to present more data of favipiravir due to current COVID-19 Situation.

Keywords: Favipiravir, COVID-19, Influenza, Nipah, Ebola.

[Full Text Article]

SJIF Impact Factor: 6.222

INDEXING

Indexing

LOGIN

NEWS & UPDATION

EJPMR: DECEMBER ISSUE PUBLISHED
December issue has been successfully launched on 1 December 2023.

New Issue Published
Its Our pleasure to inform you that, EJPMR 1 December 2023 Issue has been Published, Kindly check it on https://www.ejpmr.com/issue

EJPMR New Impact Factor
Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from 5.804 to 6.222, due to high quality Publication at International Level